Phase 3 N=454 Smartphone Based Smoking Cessation Intervention
Smoking Cessation
Primary: Biochemically-Verified Smoking Cessation — 37; 23 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=451 A Study to Evaluate Efficacy of Dotinurad and Febuxostat for the Treatment of Participants With Gout
Gout
Primary: Percentage of Participants With Serum Uric Acid (SUA) Level <=6.0 mg/dL at Week 24 (LOCF) — 38.1; 73.6 percentage of participants — p=<0.001
Phase 3 N=1,900 A Study to Evaluate the Safety and Immune Response of mRNA-1345, a Vaccine Targeting Respiratory Syncytial Virus (RSV), When Co-administered With a Fluzone HD, in Adults ≥65 Years of Age
Respiratory Syncytial Virus
Primary: Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs) Within 7 Days After Day 1 Injection — 689; 547 Participants
Phase 3 N=52 Study to Assess Bronchospasm Potentially Induced by Next-Generation Propellant vs HFA Propellant in an MDI in Participants With Well/Partially Controlled Asthma
Asthma
Primary: Change From Baseline in Normalized Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve From 0 to 15 Minutes (AUC0-15 Min) Post-dose — 2.969; 2.970; 2.955…
Phase 3 N=271 Sickle Cell Disease Treatment With Arginine Therapy (STArT) Trial
Sickle Cell Disease
Primary: Time-to-crisis Resolution — 81.5; 88.6 hours
Phase 3 N=133 Use of Epidurals Intraoperatively for Patients Undergoing Pancreas Resection
Pancreatic Cancer
Primary: Number of Incidences of Grade 3 or Greater Complications — 0; 0 Number of complications
Phase 3 N=207 A Study to Test the Safety/ Efficacy of Brivaracetam (BRV) Used as Adjunctive Treatment in Subjects >=16 Years of Age With Partial Seizures With or Without Secondary Generalization
Partial Seizures With or Without Secondary Generalization · Epilepsy
Primary: Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) — 88.9; 95.5; 100; 94.1 percentage of participants
Phase 3 N=122 Eltrombopag vs Standard Front Line Management for Newly Diagnosed Immune Thrombocytopenia (ITP) in Children
Immune Thrombocytopenia
Primary: Proportion of Patients With a Platelet Response — 52; 14 Participants
Phase 3 N=792 ODYSSEY (PENTA 20)
HIV Infection
Primary: Difference in Proportion With Failure (Clinical or Virological) — 0; 3; 0; 0 Participants — p== 0.004
Phase 3 N=619 To Compare Efficacy and Safety of CT-P39 and EU-approved Xolair in Patients With Chronic Spontaneous Urticaria
Chronic Spontaneous Urticaria
Primary: Therapeutic Equivalence Based on Change From Baseline in ISS7 at Week 12 in 300 mg Groups — -9.25; -9.96 score on a scale
Phase 3 N=55 Lebrikizumab Pen Ease of Use in Participants With Atopic Dermatitis
Atopic Dermatitis
Primary: Percentage of Participants Who Responded Agree or Strongly Agree to the 'Overall Ease of Use' Question Using the Modified Subcutaneous Administration Assessment…
Phase 3 N=529 Fixed-Dose Trial in Early Parkinson's Disease (PD)
Parkinson Disease
Primary: Change From Baseline in the MDS-UPDRS Parts II and III Combined Score — 1.8; -9.7; -10.2 score on a scale — p=<0.0001
Phase 3 N=120 A Study of PEGylated Recombinant Factor VIII (BAX855) in Previously Untreated Young Children With Severe Hemophilia A
Hemophilia A
Primary: Number of Participants With FVIII Inhibitor Development — 11 Participants
Phase 3 N=9 Late-onset Sepsis in Term and Pre-term Neonates and Infants up to 3 Months of Age
Neonatal Sepsis
Primary: Number of Patients With Adverse Events (AEs) — 3; 3; 0; 0 Participants
Phase 3 N=169 Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Double Lung Transplant (BOSTON-2)
Bronchiolitis Obliterans · Chronic Rejection of Lung Transplant · Lung Transplant Rejection
Primary: Mean Change in FEV1 (Liters) From Baseline to Week 48 — -0.096; -0.067 Liters — p=0.6639